Endocan is a marker showing endothelial dysfunction and inflammation. Significantly increased endocan levels have been observed in serum of patients with sepsis and cancer.
Objective:
Our aim was to investigate the relationship between vitamin D treatment and serum endocan and high-sensitivity C-reactive protein (hs-CRP) levels as inflammatory markers in transplant patients.
Design:
Prospective.
Setting:
Nephrology clinic.
Patients:
Thirty-eight renal transplant patients with serum 25-hydroxy-vitamin D (25-OH-vitamin D) levels below 20 ng/mL and transplanted at least 12 months.
Intervention:
One-time oral dose of 300 000 IU vitamin D3.
Main Outcome Measures:
Before and after vitamin D treatment, serum endocan, hs-CRP, calcium, phosphorus, and parathyroid hormone (PTH) levels were measured.
Results:
Median serum endocan and PTH values before vitamin D were significantly higher than those of after treatment values (P = .001 and P < .001, respectively). On the other hand, serum total calcium and phosphorus levels before vitamin D treatment were lower than the values obtained after vitamin D treatment (P = .0013 and P < .001, respectively). Serum hs-CRP was lower after vitamin D therapy than before, but the difference was not statistically significant (P = .06). A moderate negative correlation was determined between endocan and 25-OH-vitamin D levels after treatment with vitamin D (r = −.36, P = .02).
Conclusion:
This study has revealed that vitamin D treatment reduced markers of endothelial dysfunction in patients with renal transplantation and vitamin D deficiency.
WeisingerJRCarliniRGRojasEBellorin-FontE. Bone disease after renal transplantation. Clin J Am Soc Nephrol. 2006;1(6):1300–1313.
2.
Cueto-ManzanoAMKonelSFreemontAJ. Effect of 1, 25-dihydroxyvitamin D3 and calcium carbonate on bone loss associated with long-term renal transplantation. Am J Kidney Dis. 2000;35(2):227–236.
3.
KocMTuglularSArikanHOzenerCAkogluE. Alendronate increases bone mineral density in long-term renal transplant recipients. Transplant Proc. 2002;34(6):2111–2113.
4.
HolickMF. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutr. 2004;80(6 suppl):1678S–1688S.
5.
HolickMF. Resurrection of vitamin D deficiency and rickets. J Clin Invest. 2006;116(8):2062–2072.
6.
KocakHCekenKYavuzA. Effect of renal transplantation on endothelial function in haemodialysis patients. Nephrol Dial Transplant. 2006;21(1):203–207.
7.
Al MheidIPatelRMurrowJ. Vitamin D status is associated with arterial stiffness and vascular dysfunction in healthy humans. J Am Coll Cardiol. 2011;58(2):186–192. doi:10.1016/j.jacc.2011.02.051.
8.
BéchardDGentinaTDeleheddeM. Endocan is a novel chondroitin sulfate/dermatan sulfate proteoglycan that promotes hepatocyte growth factor/scatter factor mitogenic activity. J Biol Chem. 2001;276(51):48341–48349.
9.
LassallePMoletSJaninA. ESM-1 is a novel human endothelial cell-specific molecule expressed in lung and regulated by cytokines. J Biol Chem. 1996;271(34):20458–20464.
10.
BechardDMeigninVScherpereelA. Characterization of the secreted form of endothelial-cell-specific molecule 1 by specific monoclonal antibodies. J Vasc Res. 2000;37(5):417–425.
11.
ScherpereelAGentinaTGrigoriuB. Overexpression of endocan induces tumor formation. Cancer Res. 2003;63(18):6084–6089.
12.
GanesanKTeklehaimanotSTranTHAsuncionMNorrisK. Relationship of C-reactive protein and bone mineral density in community-dwelling elderly females. J Natl Med Assoc. 2005;97(3):329–333.
13.
GepnerADRamamurthyRKruegerDCKorcarzCEBinkleyNSteinJH. A prospective randomized controlled trial of the effects of vitamin D supplementation on cardiovascular disease risk. PLoS One. 2012;7(5):36617. doi:10.1371/journal.pone.0036617.
14.
ZhangYLeungDYRichersBN. Vitamin D inhibits monocyte/macrophage proinflammatory cytokine production by targeting MAPK phosphatase-1. J Immunol. 2012;188(5):2127–2135. doi:10.4049/jimmunol.1102412.
15.
ObiYHamanoTIsakaY. Prevalence and prognostic implications of vitamin D deficiency in chronic kidney disease. Dis Markers. 2015;2015:868961. doi:10.1155/2015/868961.
16.
EwersBGasbjergAMoelgaardCFrederiksenAMMarckmannP. Vitamin D status in kidney transplant patients: need for intensified routine supplementation. Am J Clin Nutr. 2008;87(2):431–437.
17.
MarcénRPonteBRodríguez-MendiolaN. Vitamin D deficiency in kidney transplant recipients: risk factors and effects of vitamin D3 supplements. Transplant Proc. 2009;41(6):2388–2390. doi:10.1016/j.transproceed.2009.06.050.
18.
QueringsKGirndtMGeiselJGeorgTTilgenWReichrathJ. 25-hydroxyvitamin D deficiency in renal transplant recipients. J Clin Endocrinol Metab. 2006;91(2):526–529.
19.
StavroulopoulosACassidyMJPorterCJHoskingDJRoeSD. Vitamin D status in renal transplant recipients. Am J Transplant. 2007;7(11):2546–2552.
20.
ReichelHGrüssingerAKnehansAKühnKSchmidt-GaykHRitzE. Long-term therapy with cyclosporin A does not influence serum concentrations of vitamin D metabolites in patients with multiple sclerosis. Clin Investig. 1992;70(7):595–599.
21.
RobienKOppeneerSJKellyJAHamilton-ReevesJM. Drug-vitamin D interactions: a systematic review of the literature. Nutr Clin Pract. 2013;28(2):194–208. doi:10.1177/0884533612467824.
22.
PaciniSPunziTGulisanoM. Vitamin D receptor alleles and C-reactive protein in hemodialysis patients. Ital J Anat Embryol. 2008;113(1):55–62.
23.
Pérez-LópezFR. Vitamin D metabolism and cardiovascular risk factors in postmenopausal women. Maturitas. 2009;62(3):248–262. doi:10.1016/j.maturitas.2008.12.020.
24.
ReindersMERabelinkTJBriscoeDM. Angiogenesis and endothelial cell repair in renal disease and allograft rejection. J Am Soc Nephrol. 2006;17(4):932–942.
25.
LiSWangLWangC. Detection on dynamic changes of endothelial cell specific molecule-1 in acute rejection after renal transplantation. Urology. 2012;80(3):738.e1–e8. doi:10.1016/j.urology.2012.03.019.
26.
BaltaSMikhailidisDPDemirkolSOzturkCCelikTIyisoyA. Endocan: a novel inflammatory indicator in cardiovascular disease?Atherosclerosis. 2015;243(1):339–343. doi:10.1016/j.atherosclerosis.2015.09.030.
27.
WangXSYangWLuoTWangJMJingYY. Serum endocan levels are correlated with the presence and severity of coronary artery disease in patients with hypertension. Genet Test Mol Biomarkers. 2015;19(3):124–127. doi:10.1089/gtmb.2014.0274.
28.
SuYHShuKHHuCP. Serum endocan correlated with stage of chronic kidney disease and deterioration in renal transplant recipients. Transplant Proc. 2014;46(2):323–327. doi:10.1016/j.transproceed.2013.10.057.
29.
MihajlovicDMLendakDFBrkicSV. Endocan is useful biomarker of survival and severity in sepsis. Microvasc Res. 2014;93:92–97. doi:10.1016/j.mvr.2014.04.004.
30.
BaltaSMikhailidisDPDemirkolS. Endocan—a novel inflammatory indicator in newly diagnosed patients with hypertension: a pilot study. Angiology. 2014;65(9):773–777. doi:10.1177/0003319713513492.
31.
BaltaIBaltaSKoryurekOM. Serum endocan levels as a marker of disease activity in patients with Behçet disease. J Am Acad Dermatol. 2014;70(2):291–296. doi:10.1016/j.jaad.2013.09.013.
32.
YankouskayaLSnezhitskiyV. Relationship between vascular endothelial function and vitamin D and parathyroid hormone levels in women with arterial hypertension. Pol Arch Med Wewn. 2014;124(10):532–539.
